Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 356-364

  Tsunematsu, Hinako ^a   Tatsumi, Tomohide ^a   Kohga, Keisuke ^a   Yamamoto, Masashi ^a   Aketa, Hiroshi ^a   Miyagi, Takuya ^a   Hosui, Atsushi ^a   Hiramatsu, Naoki ^a   Kanto, Tatsuya ^a   Hayashi, Norio ^b   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

FGF 2; hepatocellular carcinoma; HLA class I; MICA; NK cells

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; HLA ANTIGEN CLASS 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS 1 RELATED CHAIN A; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOMA CELL; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 83655192116     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26003     Document Type: Article

References (23)

1. Pang R, Poon RT,. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242: 151-67.
2. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M,. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23: 455-64.
3. Chow NH, Cheng KS, Lin PW, Chan SH, Su WC, Sun YN, Lin XZ,. Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma. Dig Dis Sci 1998; 43: 2261-6.
4. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N,. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001; 7: 1299-305.
5. Kin M, Sata M, Ueno T, Torimura T, Inuzuka S, Tsuji R, Sujaku K, Sakamoto M, Sugawara H, Tamaki S, Tanikawa K,. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997; 27: 677-87.
6. Uematsu S, Higashi T, Nouso K, Kariyama K, Nakamura S, Suzuki M, Nakatsukasa H, Kobayashi Y, Hanafusa T, Tsuji T, Shiratori Y,. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 583-8.
7. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and trends. Gastroenterology 2004; 127: S35-50.
8. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
9. Doherty DG, O'Farrelly C,. Innate and adaptive lymphoid cells in human liver. Immunol Rev 2000; 174: 5-20.
10. Mehal WZ, Azzaroli F, Crispe IN,. Immunology of the healthy liver: old questions and new insights. Gatsroenterology 2001; 120: 250-60.
11. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH,. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-80.
12. Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N,. Anti-cancer chemotherapy inhibits MICA ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009; 69: 8050-7.
13. Lapinski TW,. The levels of IL-1β, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch Immunol Ther Exp 2001; 49: 311-16.
14. Bortolami M, Kotsafti A, Cardin R, Farinati F,. Fas/FasL system, IL-1β expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 2008; 15: 515-22.
15. Migita K, Abiru S, Maeda Y, Daikoku M, Ohata K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H,. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Human Immunol 2005; 67: 27-32.
16. Jinno K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T,. Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 1997; 32: 119-21.
17. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Huber J, Nakatani T, Tsujinoue H, Yanase K, Imazu H, Fukui H,. Synergistic effects of basic fibroblast growth factor and vascular endotherial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-42.
18. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, Kuo ML,. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 2004; 123: 1169-75.
19. Faris M, Ensoli B, Kokot N, Nel AE,. Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. AIDS 1998; 12: 19-27.
20. Oyanagi Y, Takahashi T, Matsui S, Takahashi S, Boku S, Takahashi K, Furukawa K, Arai F, Asakura H,. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 1999; 19: 464-72.
21. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N,. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-61.
22. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N,. Sorafenib inhibits the shedding of MICA on hepatocellular cacrcinoma cell by downregulating ADAM9. Hepatology 2010; 51: 1264-73.
23. Champsaur M, Lanier LL,. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-85.